Benzinga's Top Upgrades

Analysts at Morgan Stanley upgraded Bristol-Myers Squibb Company BMY from “equal-weight” to “overweight.” The target price for Bristol-Myers Squibb has been raised from $45 to $60. Bristol-Myers Squibb's shares closed at $48.77 on Friday. Analysts at Goldman Sachs upgraded Generac Holdings GNRC from “sell” to “neutral.” The target price for Generac Holdings has been raised from $32 to $49. Generac's shares closed at $50.44 on Friday. Guggenheim Securities upgraded FMC Technologies FTI from “neutral” to “buy.” The target price for FMC Technologies is set to $60. FMC Technologies' shares closed at $51.13 on Friday. Analysts at Bank of America upgraded Astrazeneca PLC AZN from “underperform” to “neutral.” Astrazeneca's shares closed at $52.74 on Friday.